Catalyst Event
Caris Life Sciences Inc (CAI) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/23/2026, 12:00:00 AM
Began presenting five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting from March 23-24, 2026, showcasing new data across multiple cancer types. Low importance is estimated as scientific presentations typically result in a ≥1% price impact, scheduled.
Korean Translation
2026년 3월 23일부터 24일까지 개최되는 2026년 미국-캐나다 병리학회(USCAP) 연례 회의에서 여러 암 유형에 걸친 새로운 데이터를 보여주는 5개의 연구 발표를 시작함. 학술 데이터 발표는 통상 1% 이상의 주가 영향을 미츘므로 'Low'로 평가함. 예정됨.
Related Recent Events
Adaptive Biotechnologies Corp (ADPT) · Earnings Release
First quarter 2026 earnings release scheduled.
5/6/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Earnings Release
Q1 2026 earnings release is scheduled. Analysts forecast an EPS of -$0.27, forecasted and scheduled. A low impact is estimated as the market typically reacts to actual results.
5/4/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
AbbVie is scheduled to release its Q1 2026 financial results on April 24, 2026, with analysts forecasting EPS around $3.01-$3.02 and revenue of approximately $14.72 billion; Medium importance is estimated based on typical earnings price impact, scheduled.
4/24/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q1 2026 earnings release is scheduled for April 23, 2026, scheduled.
4/23/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Eli Lilly announced positive top-line results from its TRANSCEND-T2D-1 Phase 3 trial for retatrutide, a next-generation obesity and diabetes drug. The study showed significant reductions in both A1C levels and body weight in adults with type 2 diabetes, expected. High importance is estimated as positive Phase 3 results for a major drug typically result in a price impact exceeding 10%.
3/19/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Other
AbbVie's stock price declined on March 18, 2026, following FDA approvals in early March for competitor immunology drugs from Johnson & Johnson (ICOTYDE) and Bristol Myers Squibb (Sotyktu), increasing competition for AbbVie's products.
3/18/2026, 12:00:00 AM